Robert Forrester served as the CEO of Verastem, Inc., from July 2013 until June 2019. His journey in the pharmaceutical industry is quite extensive. Before taking the helm at Verastem, he was the Chief Operating Officer at Forma Therapeutics and...
Robert Forrester served as the CEO of Verastem, Inc., from July 2013 until June 2019. His journey in the pharmaceutical industry is quite extensive. Before taking the helm at Verastem, he was the Chief Operating Officer at Forma Therapeutics and played key roles in companies like CombinatoRx and Coley Pharmaceuticals. During his tenure at Verastem, he was instrumental in pursuing the approval of the drug duvelisib, aiming to bring new treatment options to patients. His compensation varied significantly over the years, peaking at over $2.5 million in 2015 under a performance-driven pay structure. An interesting note is that his last year at Verastem saw a considerable stock options grant, which aligned with the company’s corporate performance. Despite his departure in 2019, Forrester continues to be connected to the industry through consulting roles and board memberships, showing that his insights are still valued. Additionally, his stock transactions showed an increasing trend, hinting at his confidence in the company’s future during his final years, peaking at over $960K in one month in June 2021.